Vargas, H. M., Rolf, M. G., Wisialowski, T. A., Achanzar, W., Bahinski, A., Bass, A., Benson, C. T., Chaudhary, K. W., Couvreur, N., Dota, C., Engwall, M. J., Michael Foley, C., Gallacher, D., Greiter‐Wilke, A., Guillon, J., Guth, B., Himmel, H. M., Hegele‐Hartung, C., Ito, M., Jenkinson, S., Chiba, K., Lagrutta, A., Levesque, P., Martel, E., Okai, Y., Peri, R., Pointon, A., Qu, Y., Teisman, A., Traebert, M., Yoshinaga, T., Gintant, G. A., Leishman, D. J., & Valentin, J. (2021). time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective. Clinical pharmacology & therapeutics, 109(2), 310–318. http://access.bl.uk/ark:/81055/vdc_100119953466.0x00005f